Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.31
+0.02 (0.27%)
At close: Apr 28, 2026, 4:00 PM EDT
7.27
-0.04 (-0.55%)
After-hours: Apr 28, 2026, 7:15 PM EDT
Kezar Life Sciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Kezar Life Sciences stock have an average target of 6.00, with a low estimate of 5.00 and a high estimate of 7.00. The average target predicts a decrease of -17.92% from the current stock price of 7.31.
Analyst Consensus: Hold
* Price targets were last updated on Oct 17, 2025.
Analyst Ratings
The average analyst rating for Kezar Life Sciences stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $18 → $7 | Strong Buy → Hold | Downgrades | $18 → $7 | -4.24% | Oct 17, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 17, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | -31.60% | Oct 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jul 16, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +23.12% | Dec 19, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.01
from -7.66
EPS Next Year
-2.89
from -3.01
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.95 | -0.07 | |||
| Avg | -3.01 | -2.89 | |||
| Low | -4.37 | -6.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.